![](/img/cover-not-exists.png)
Ocrelizumab in multiple sclerosis: risks and benefits – Author's reply
Ludwig Kappos, David Leppert, Jeroen Timmermann, Robert Glanzman, Stephen HauserVolume:
379
Year:
2012
Language:
english
DOI:
10.1016/s0140-6736(12)60509-1
File:
PDF, 80 KB
english, 2012